Polypeptide that binds aberrant cells and induces apoptosis

a polypeptide and aberrant cell technology, applied in the field of biotherapeutics, can solve the problems of affecting the therapeutic application of these anti-mhc antibodies, lack of target cell specificity, and cancer development, and achieve the effects of improving the ability to reverse thermal denaturation, improving affinity and stability, and improving the ability to bind aberrant cells

Inactive Publication Date: 2018-03-15
APO T
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The approach enables selective targeting and induction of apoptosis in aberrant cells, such as cancer cells, with minimal impact on healthy cells, potentially enhancing cancer treatment efficacy and reducing side effects.

Problems solved by technology

However, if the transformed cells resist immune-mediated cell killing, cancer may develop.
However, the therapeutic application of these anti-MHC antibodies has been hampered by the lack of target cell specificity.
As a consequence, their therapeutic value is significantly reduced, if not abolished by the side effects caused by unwanted apoptosis of healthy cells.
Obtaining antibodies binding to MHC-p complexes and not binding to MHC molecules not loaded with the antigenic peptide remains a laborious task and several failures have been reported.
Immunization with MHC-p complexes is extremely time consuming.
Moreover, antibodies of murine origin cannot be used repetitively in patients because of the likely development of a human anti-mouse antibody response (so-called anti-drug antibodies, ADA).
Antibodies derived from phage display, in general, display low affinity for the antigen and thus may require additional modifications before they can be used efficiently.
Cancer is caused by oncogenic transformation in aberrant cells, which drives uncontrolled cell proliferation, leading to misalignment of cell-cycle checkpoints, DNA damage and metabolic stress.
Thus, cancer cells can grow, not only due to imbalances in proliferation and / or cell cycle regulation, but also due to imbalances in their apoptosis machinery.
Traditional cancer therapies can activate apoptosis, but they do so indirectly and often encounter tumor resistance.
A disadvantage of many, if not all, anti-tumor drugs currently on the market or in development, which are based on targeting the apoptosis machinery, is that these drugs do not discriminate between aberrant cells and healthy cells.
This non-specificity bears a challenging risk for drug-induced adverse events.
Therefore, a disadvantage of current apoptosis-inducing compounds is their non-selective nature, which reduces their potential.
Fortunately, these viruses (or their proteins) have the ability to efficiently target cell death program in aberrant cells, although this cell death program might be derailed as a consequence of its aberrant nature.
The various clinical trials revealed that the therapeutic agents were selective for cancer cells, but therapeutic potency was limited.
In general, anti-tumor gene therapy has largely failed to date in patients owing to inefficient delivery of the gene to sufficient numbers of cancer cells locally and systemically.
In the nuclei of tumor cells, HAMLET associates with histones resulting in an irreversible disruption of the chromatin organization.
TRAIL's apoptosis activity is selective for tumor cells but the diversity of tumor cells susceptible to TRAIL-induced apoptosis is limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide that binds aberrant cells and induces apoptosis
  • Polypeptide that binds aberrant cells and induces apoptosis
  • Polypeptide that binds aberrant cells and induces apoptosis

Examples

Experimental program
Comparison scheme
Effect test

example 1

Selection of Human Antibody Fragments Specific for HLA-A0201 / Multi-MAGE-A

[0106]To obtain human antibody fragments specific for the HLA-A0201-presented multi-MAGE-A epitope Y-L-E-Y-R-Q-V-P-G (SEQ ID NO:11) or Y-L-E-Y-R-Q-V-P-V (SEQ ID NO:23), a Human Fab phage display library was constructed according to the procedure previously described by de Haard et al.(2) and used for selections essentially as described by Chames et al.(3) Alternatively, a human VhCh library was constructed and used for selections. Human Fab / VhCh phages (1013 colony-forming units) were first pre-incubated for 1 hour at room temperature in PBS containing 2% non-fat dry milk (PB SM). In parallel, 200 μl Streptavidin-coated beads (Dynal™) were equilibrated for 1 hour in PBSM. For subsequent rounds, 100 μl beads were used. To deplete for pan-MHC binders, each selection round, 200 nM of biotinylated MHC class I-peptide (MHC-p) complexes containing an irrelevant peptide (Sanquin, the Netherlands) were added to the pha...

example 2

Production of Monovalent and Multivalent AH5-Apoptin Polypeptides and Monovalent and Multivalent AH5-Cath-Apoptin Polypeptides

Design of Genes for Production of Tetrameric AH5 VH-Apoptin and AH5 Vh-Cath-Apoptin

[0110]Human antibody germline gene VH3 demonstrates high homology to llama single domains VHH. Exchange of amino-acids 44, 45 and 47 in the human VH3 genes by amino-acids present in llama VHH at these positions has shown to enhance stability and expression of the human VH3 genes. All substitutions described to have an effect on protein stability and / or solubility include: E6A, A33C, V37F, G44E, L45R, W47G, S74A, R83K, A84P or L108Q.

[0111]The AH5 VH demonstrates a low homology to germline gene VH3-33*01 (71% as determined by IMGT homology search); however, its expression and stability might benefit from the exchange of amino-acids 6, 44, 45 and 47 and 108 by llama VHH amino-acid residues, a process called camelization. In addition, a gene was compiled that upon expression, compr...

example 3

Cell Binding and Internalization of Tetra-AH5-Cath-Apoptin

[0114]Binding capacity of tetra-AH5-cath-apoptin was analyzed by flow-cytometry. HLA-A0201 / multi-MAGE-A-positive tumor cells (Daju, MDN and mel 624) and HLA-A0201 / multi-MAGE-A-negative cells (BSM, G43 and 293) were incubated on ice with purified protein and detected by addition of fluorescently labeled anti-His antibodies. Cells bound by the proteins were quantified and visualized by flow cytometry. Internalization of tetra-AH5-cath-apoptin was analyzed by confocal microscopy. To this end, cells were incubated with the proteins, kept on ice for 30 minutes to allow binding but no internalization. Next, fluorescently labeled anti-His antibodies were added. To induce internalization, cells were transferred to 37° C. and fixed with 1% PFA after 5, 10 and 15 minutes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described are proteinaceous molecules comprising at least a domain that comprises an amino acid sequence that specifically binds to an MHC-peptide complex on an aberrant cell, functionally connected with a substance that induces apoptosis in aberrant cells, but not in normal cells. These proteinaceous molecules are preferably used in selectively modulating biological processes. The provided proteinaceous molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of co-pending U.S. patent application Ser. No. 13 / 976,974, filed Nov. 14, 2013, U.S. Pat. No. 9,821,073 (Nov. 21, 2017), and which is a national phase entry under 35 U.S.C. § 371 of International Patent Application PCT / NL2011 / 050891, filed Dec. 22, 2011, designating the United States of America and published in English as International Patent Publication WO 2012 / 091563 A1 on Jul. 5, 2012, which claims the benefit under Article 8 of the Patent Cooperation Treaty and under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 61 / 460,212, filed Dec. 27, 2010, the contents of the entirety of each of which is incorporated herein by this reference.TECHNICAL FIELD[0002]The application relates to the field of biotherapeutics. It also relates to the field of tumor biology. More in particular, it relates to specific binding molecules that induce cell death, in particular, programmed cell death (apopto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): C07K16/28C07K16/30A61K45/06
CPCA61K45/06C07K16/2833C07K16/30C07K2317/21C07K2317/24C07K2317/32C07K2317/35C07K2317/55C07K2317/56C07K2317/73C07K2319/00C07K2317/34A61K47/64A61P35/00A61K47/6851
InventorWILLEMSEN, RALPH ALEXANDERRENES, JOHAN
OwnerAPO T